Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

Inclusion Criteria:

• HIV-1-infected patient
• Age > 65 years old
• Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml isallowed in the past 6 months before screening.
• Currently receiving an antiretroviral regimen containing a booster, ritonavir orcobicistat
• No resistance mutation to integrase inhibitors on cumulative HIV RNA genotype. Thereverse transcriptase resistant mutations M184V plus one TAM are allowed.
• If no genotype is available, DNA genotype will be performed at screening visit: noresistance mutation to integrase inhibitors, the reverse transcriptase resistantmutations M184V plus one TAM are allowed.
• Patient enrolled in or a beneficiary of a Social Security program (State Medical Aidor AME is not a Social Security program)
• Informed consent form signed by patient and investigator

Exclusion Criteria:

• HIV-2 infection
• Currently receiving one of the following drugs: Hypericum perforatum, rifampicin,rifabutin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, sucralfate,cyclosporine, primidone, ténofovir et adéfovir.
• Hemoglobin < 10g/dL
• Platelets < 100 000/mm3
• Hepatic transaminases AST and ALT > 3x upper limit of normal (ULN)
• Severe hepatic insufficiency (Child Pugh Class C)
• Creatininemia clairance < 30 mL/min (MDRD)
• History or presence of allergy to the trial drugs or their components
• Patients participating in another clinical trial including an exclusion period that isstill ongoing during the screening phase
• Patients under judicial protection due to temporarily and slightly diminished mentalor physical faculties or under legal guardianship.